NA
BCRX icon

NewEdge Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

NewEdge Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531K Buy
53,099
+773
+1% +$6.99K ﹤0.01% 2101
2026
Q1 		$498K Buy
52,326
+2,285
+5% +$17.7K ﹤0.01% 1993
2025
Q4 		$390K Buy
+50,041
New +$362K ﹤0.01% 2140
2025
Q2 		– Sell
-11
Closed -$83 – 3995
2025
Q1 		$83 Hold
11
– – ﹤0.01% 3833
2024
Q4 		$83 Buy
+11
New +$84 ﹤0.01% 3790
2023
Q4 		– Sell
-30
Closed -$212 – 3758
2023
Q3 		$212 Hold
30
– – ﹤0.01% 3320
2023
Q2 		$211 Sell
30
-4,078
-99% -$32.7K ﹤0.01% 3381
2023
Q1 		$34.3K Sell
4,108
-4,217
-51% -$40.6K ﹤0.01% 2154
2022
Q4 		$96 Buy
+8,325
New +$104K ﹤0.01% 3380
2022
Q2 		– Sell
-11,495
Closed -$187K – 1564
2022
Q1 		$187K Sell
11,495
-1,123
-9% -$18K ﹤0.01% 1026
2021
Q4 		$175K Sell
12,618
-1,637
-11% -$21.7K ﹤0.01% 1538
2021
Q3 		$205K Buy
14,255
+1,964
+16% +$31K 0.01% 1047
2021
Q2 		$194K Sell
12,291
-115
-0.9% -$1.56K 0.01% 1056
2021
Q1 		$126K Buy
+12,406
New +$128K ﹤0.01% 976
2020
Q4 		– Sell
-24,000
Closed -$82K – 981
2020
Q3 		$82K Buy
+24,000
New +$103K ﹤0.01% 875

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

NewEdge Advisors's BCRX Position: Q2 2026 in Review

NewEdge Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 1.5% in Q2 2026, buying an estimated $6.99K and bringing the position to 53,099 shares worth $531K. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

NewEdge Advisors first reported a position in BCRX in Q3 2020 and has held it in 15 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • NewEdge Advisors held 53,099 shares of BioCryst Pharmaceuticals worth $531K as of Q2 2026.
  • NewEdge Advisors bought 773 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $6.99K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2101 holding.
  • NewEdge Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2020 and has held it in 15 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.